Furthermore, IBR2 improves survival when given to a mouse model with drug-resistant CML and inhibits the proliferation of CD34+ progenitor cells derived from CML patients [167]. Here, CD34 is linked to chronic myelogenous leukemia, BCR-ABL1 positive.